Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Goodrx Holdings Inc Cl A (NQ: GDRX )

6.190 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 6.190
Bid (Size) 6.000 (1)
Ask (Size) 6.950 (5)
Prev. Close 6.190
Today's Range 6.190 - 6.190
52wk Range 4.135 - 9.260
Shares Outstanding 412,429,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
GoodRx Unveils New E-commerce Platform, Launches with Opill®
From GoodRx
Via Business Wire
GoodRx Announces Exclusive Low Cash Price for QSYMIA®, the Leading Branded Once-Daily Oral Weight Management Medication for Adults
From GoodRx
Via Business Wire

Performance

YTD
+10.14%
+10.14%
1 Month
-12.69%
-12.69%
3 Month
-24.97%
-24.97%
6 Month
-17.14%
-17.14%
1 Year
+16.14%
+16.14%

More News

Read More
Ronald E. Bruehlman Joins GoodRx Board of Directors
From GoodRx
Via Business Wire
GoodRx Holdings Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)
Via Benzinga
GoodRx Announces New Affordability Programs for Menopause Hormone Therapies
From GoodRx
Via Business Wire
GoodRx Partnering with Retail Pharmacies to Deliver Pay-Over-Time Option Directly to Consumers
From GoodRx
Via Business Wire
GoodRx Announces Date for Third Quarter 2024 Earnings Release and Conference Call
From GoodRx Holdings, Inc.
Via Business Wire
GoodRx Announces Lowest Discounted Cash Price at Retail Pharmacy Locations for neffy® (epinephrine nasal spray)
From GoodRx
Via Business Wire
GOODRX ALERT: Bragar Eagel & Squire, P.C. is Investigating GoodRx Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
GoodRx to Participate in Upcoming Investor Conferences
From GoodRx Holdings, Inc.
Via Business Wire
GoodRx (GDRX) Q2 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
GoodRx Reports Q2 Earnings With Increased Prescription Revenue But Subscription Challenges
Via Benzinga
GoodRx Reports Second Quarter 2024 Results
From GoodRx Holdings, Inc.
Via Business Wire
MicroStrategy, Coinbase, Robinhood, Tesla And Other Big Stocks Moving Higher On Monday
Via Benzinga
GoodRx Announces Date for Second Quarter 2024 Earnings Release and Conference Call
From GoodRx Holdings, Inc.
Via Business Wire
Ian T. Clark Joins GoodRx Board of Directors
From GoodRx Holdings, Inc.
Via Business Wire
3 Lawsuit-Laden Stocks to Dump Before Problems Multiply
Via InvestorPlace
Market Correction Alert: Sell These 3 Tech Stocks While You Can
Via InvestorPlace
GoodRx Launches New “Prescription Cost Tracker” to Spotlight Key Factors Driving Out-of-Pocket Medication Costs in the U.S.
From GoodRx
Via Business Wire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of GoodRx
From Faruqi & Faruqi LLP
Via GlobeNewswire
GDRX Investors Have Opportunity to Lead GoodRx Holdings, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
GoodRx Holdings, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - GDRX
From DJS Law Group
Via Business Wire
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against GoodRx Holdings, Inc. (GDRX)
From The Law Offices of Frank R. Cruz
Via Business Wire
GDRX Investors Have Opportunity to Lead GoodRx Holdings, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
GDRX Investors Have Opportunity to Lead GoodRx Holdings, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.